

Rachael F Grace

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/1101738/publications.pdf](https://exaly.com/author-pdf/1101738/publications.pdf)

Version: 2024-02-01

95
papers

3,032
citations

209248

26
h-index

182759

51
g-index

96
all docs

96
docs citations

96
times ranked

4048
citing authors

#	ARTICLE	IF	CITATIONS
1	Mitapivat improves ineffective erythropoiesis and iron overload in adult patients with pyruvate kinase deficiency. <i>Blood Advances</i> , 2024, 8, 2433-2441.	5.4	1
2	The 2022 review of the 2019 American Society of Hematology guidelines on immune thrombocytopenia. <i>Blood Advances</i> , 2024, 8, 3578-3582.	5.4	2
3	Clinically meaningful improvements in patient-reported outcomes in mitapivat-treated patients with pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2024, 99, 1415-1419.	4.3	0
4	Early-onset reduced bone mineral density in patients with pyruvate kinase deficiency. <i>American Journal of Hematology</i> , 2023, 98, .	4.3	4
5	Pediatric refractory immune thrombocytopenia: A systematic review. <i>Pediatric Blood and Cancer</i> , 2023, 70, .	1.6	9
6	Updates and advances in pyruvate kinase deficiency. <i>Trends in Molecular Medicine</i> , 2023, 29, 406-418.	7.1	10
7	<sc>HLA</sc> antibodies in fetal and neonatal alloimmune thrombocytopenia. <i>Transfusion</i> , 2023, 63, 1141-1149.	1.8	2
8	An update on pediatric ITP: differentiating primary ITP, IPD, and PID. <i>Blood</i> , 2022, 140, 542-555.	1.4	10
9	Health-related quality of life and fatigue in children and adults with pyruvate kinase deficiency. <i>Blood Advances</i> , 2022, 6, 1844-1853.	5.4	15
10	Characteristics and outcomes of autoimmune hemolytic anemia after pediatric allogeneic stem cell transplant. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29410.	1.6	2
11	Who should be eligible for gene therapy clinical trials in red blood cell pyruvate kinase deficiency (<sc>PKD</sc>): Toward an expanded definition of severe <sc>PKD</sc>. <i>American Journal of Hematology</i> , 2022, 97, .	4.3	3
12	Thrombopoietin receptor agonists and rituximab for treatment of pediatric immune thrombocytopenia: A systematic review and meta-analysis of prospective clinical trials. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29447.	1.6	8
13	Mitapivat versus Placebo for Pyruvate Kinase Deficiency. <i>New England Journal of Medicine</i> , 2022, 386, 1432-1442.	30.1	51
14	Diagnosis, monitoring, and management of pyruvate kinase deficiency in children. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29696.	1.6	2
15	SARS-CoV-2 vaccination in pediatric patients with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2022, 69, e29760.	1.6	3
16	Long-term risk of developing immune thrombocytopenia and hematologic neoplasia in adults with mild thrombocytopenia. <i>Blood</i> , 2022, 140, 2849-2852.	1.4	2
17	The pyruvate kinase (PK) to hexokinase enzyme activity ratio and erythrocyte PK protein level in the diagnosis and phenotype of PK deficiency. <i>British Journal of Haematology</i> , 2021, 192, 1092-1096.	2.7	16
18	International survey on <i>Helicobacter pylori</i> testing in patients with immune thrombocytopenia: Communication of the platelet immunology scientific and standardization committee. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 287-296.	4.1	14

#	ARTICLE	IF	CITATIONS
19	Tapering thrombopoietin receptor agonists in primary immune thrombocytopenia: Expert consensus based on the RAND/UCLA modified Delphi panel method. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, 69-80.	2.4	15
20	Comorbidities and complications in adults with pyruvate kinase deficiency. <i>European Journal of Haematology</i> , 2021, 106, 484-492.	2.2	21
21	Quality of life is an important indication for second-line treatment in children with immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29023.	1.6	5
22	Refractory autoimmune cytopenias in pediatric Evans syndrome with underlying systemic immune dysregulation. <i>European Journal of Haematology</i> , 2021, 106, 783-787.	2.2	11
23	Recommendations for the clinical and laboratory diagnosis of VITT against COVID-19: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 1585-1588.	4.1	133
24	The SSC platelet immunology register of VITT and VIITP: Toward standardization of laboratory and clinical parameters. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2094-2095.	4.1	4
25	Pyruvate kinase deficiency in children. <i>Pediatric Blood and Cancer</i> , 2021, 68, e29148.	1.6	11
26	Extensive variability in platelet, bleeding, and QOL outcome measures in adult and pediatric ITP: Communication from the ISTH SSC subcommittee on platelet immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2348-2354.	4.1	9
27	Definition of a critical bleed in patients with immune thrombocytopenia: Communication from the ISTH SSC Subcommittee on Platelet Immunology. <i>Journal of Thrombosis and Haemostasis</i> , 2021, 19, 2082-2088.	4.1	15
28	Response to rituximab in children and adults with immune thrombocytopenia (ITP). <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021, 5, e12587.	2.4	5
29	Survey of 275 Patients and Caregivers Affected By Pyruvate Kinase Deficiency: Impact of Communication with Hematologists on Mental Health and Quality of Life. <i>Blood</i> , 2021, 138, 1948-1948.	1.4	0
30	Bone Mineral Density Remains Stable in Pyruvate Kinase Deficiency Patients Receiving Long-Term Treatment with Mitapivat. <i>Blood</i> , 2021, 138, 924-924.	1.4	3
31	Characterizing Iron Overload By Age in Patients Diagnosed with Pyruvate Kinase Deficiency - a Descriptive Analysis from the Peak Registry. <i>Blood</i> , 2021, 138, 3074-3074.	1.4	0
32	Rationale and Design of a Phase 3b Multicenter, Randomized, Double-Blind Placebo-Controlled, Parallel-Group Trial with an Open-Label Extension Phase to Evaluate the Efficacy and Safety of Avatrombopag for the Treatment of Pediatric Patients with Immune Thrombocytopenia. <i>Blood</i> , 2021, 138, 4211-4211.	1.4	1
33	Standardizing the Diagnostic and Therapeutic Approach to Newly Diagnosed Children with ITP: An ITP Consortium of North America (ICON) Quality Improvement Initiative. <i>Blood</i> , 2021, 138, 755-755.	1.4	1
34	Genetic variants in toll-like receptor 4 are associated with lack of steroid responsiveness in pediatric ITP patients. <i>American Journal of Hematology</i> , 2020, 95, 395-400.	4.3	5
35	Pyruvate kinase deficiency in a newborn with extramedullary hematopoiesis in the skin. <i>Blood</i> , 2020, 136, 770-770.	1.4	1
36	Management of pyruvate kinase deficiency in children and adults. <i>Blood</i> , 2020, 136, 1241-1249.	1.4	49

#	ARTICLE	IF	CITATIONS
37	Characterization of the severe phenotype of pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, E281.	4.3	8
38	Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1. Journal of Allergy and Clinical Immunology, 2020, 146, 1194-1200.e1.	2.9	105
39	The role of romiplostim for pediatric patients with immune thrombocytopenia. Therapeutic Advances in Hematology, 2020, 11, 204062072091299.	2.5	19
40	COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation. Pediatric Blood and Cancer, 2020, 67, e28382.	1.6	35
41	Fatigue in children and adolescents with immune thrombocytopenia. British Journal of Haematology, 2020, 191, 98-106.	2.7	21
42	Genotype-phenotype correlation and molecular heterogeneity in pyruvate kinase deficiency. American Journal of Hematology, 2020, 95, 472-482.	4.3	52
43	The variable manifestations of disease in pyruvate kinase deficiency and their management. Haematologica, 2020, 105, 2229-2239.	3.5	33
44	Extensive Variability in Platelet Count, Bleeding, and Quality of Life Outcome Measures in Adult and Pediatric Immune Thrombocytopenia: An Appraisal from a Critical Review of the Literature. Blood, 2020, 136, 45-46.	1.4	1
45	Characteristics of Children and Adults Treated with Rituximab for Immune Thrombocytopenia (ITP). Blood, 2020, 136, 38-39.	1.4	0
46	Tapering Thrombopoietin Receptor Agonists in Primary Immune Thrombocytopenia: Recommendations Based on the RAND/UCLA Modified Delphi Panel Method. Blood, 2020, 136, 6-8.	1.4	0
47	Safety and Efficacy of Mitapivat in Pyruvate Kinase Deficiency. New England Journal of Medicine, 2019, 381, 933-944.	30.1	123
48	Association of a positive direct antiglobulin test with chronic immune thrombocytopenia and use of second line therapies in children: A multi-institutional review. American Journal of Hematology, 2019, 94, 461-466.	4.3	8
49	How we manage patients with pyruvate kinase deficiency. British Journal of Haematology, 2019, 184, 721-734.	2.7	71
50	Second-line treatments in children with immune thrombocytopenia: Effect on platelet count and patient-centered outcomes. American Journal of Hematology, 2019, 94, 741-750.	4.3	38
51	Pediatric Hematology. Hematology/Oncology Clinics of North America, 2019, 33, xiii-xiv.	2.0	1
52	American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Advances, 2019, 3, 3829-3866.	5.4	786
53	Prevalence and management of iron overload in pyruvate kinase deficiency: report from the Pyruvate Kinase Deficiency Natural History Study. Haematologica, 2019, 104, e51-e53.	3.5	52
54	The Effect of "Pathway" to Diagnosis for Childhood ITP on Caregiver Quality of Life at Time of Diagnosis. Blood, 2019, 134, 2174-2174.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Physician decision making in selection of secondâ€line treatments in immune thrombocytopenia in children. American Journal of Hematology, 2018, 93, 882-888.	4.3	31
56	The use of prophylactic anticoagulation during induction and consolidation chemotherapy in adults with acute lymphoblastic leukemia. Journal of Thrombosis and Thrombolysis, 2018, 45, 306-314.	2.2	32
57	Ofatumumab for acute treatment and prophylaxis of a patient with multiple relapses of acquired thrombotic thrombocytopenic purpura. Journal of Thrombosis and Thrombolysis, 2018, 46, 81-83.	2.2	14
58	Clinical spectrum of pyruvate kinase deficiency: data from the Pyruvate Kinase Deficiency Natural History Study. Blood, 2018, 131, 2183-2192.	1.4	130
59	Predictors of remission in children with newly diagnosed immune thrombocytopenia: Data from the Intercontinental Cooperative ITP Study Group Registry II participants. Pediatric Blood and Cancer, 2018, 65, e26736.	1.6	56
60	Red Blood Cell Enzyme Disorders. Pediatric Clinics of North America, 2018, 65, 579-595.	2.0	48
61	The burden of disease in pyruvate kinase deficiency: Patientsâ€™ perception of the impact on healthâ€related quality of life. European Journal of Haematology, 2018, 101, 758-765.	2.2	27
62	Pk1r Intron Splicing-Associated Mutations and Alternate Diagnoses Are Common in Pyruvate Kinase Deficient Patients with Single or No Pk1r Coding Mutations. Blood, 2018, 132, 3607-3607.	1.4	4
63	Health Related Quality of Life and Fatigue in Patients with Pyruvate Kinase Deficiency. Blood, 2018, 132, 4807-4807.	1.4	1
64	Increasing observation rates in lowâ€risk pediatric immune thrombocytopenia using a standardized clinical assessment and management plan (SCAMP [®]). Pediatric Blood and Cancer, 2017, 64, e26303.	1.6	14
65	Thrombopoietin Receptor Agonist Use in Children: Data From the Pediatric ITP Consortium of North America ICON2 Study. Pediatric Blood and Cancer, 2016, 63, 1407-1413.	1.6	72
66	Exome sequencing results in successful diagnosis and treatment of a severe congenital anemia. Journal of Physical Education and Sports Management, 2016, 2, a000885.	1.2	10
67	Second-line therapies in immune thrombocytopenia. Hematology American Society of Hematology Education Program, 2016, 2016, 698-706.	2.5	35
68	Vitamin B12 Deficiency Presenting with Neurological Dysfunction in an Adolescent. Pediatric Neurology, 2016, 62, 66-70.	2.1	5
69	Effects of AG-348, a Pyruvate Kinase Activator, on Anemia and Hemolysis in Patients with Pyruvate Kinase Deficiency: Data from the DRIVE PK Study. Blood, 2016, 128, 402-402.	1.4	5
70	Erythrocyte pyruvate kinase deficiency: 2015 status report. American Journal of Hematology, 2015, 90, 825-830.	4.3	148
71	Platelet function tests, independent of platelet count, are associated with bleeding severity in ITP. Blood, 2015, 126, 873-879.	1.4	126
72	Treatment and outcomes of immune cytopenias following solid organ transplant in children. Pediatric Blood and Cancer, 2015, 62, 214-218.	1.6	32

#	ARTICLE	IF	CITATIONS
73	Thrombopoietin-receptor agonists in children with immune thrombocytopenia. <i>Lancet, The</i> , 2015, 386, 1606-1609.	12.1	3
74	Molecular Characterization of 140 Patients in the Pyruvate Kinase Deficiency (PKD) Natural History Study (NHS): Report of 20 New Variants. <i>Blood</i> , 2015, 126, 3337-3337.	1.4	4
75	DRIVE PK: A Phase 2 Trial of AG-348 in Patients with Pyruvate Kinase Deficiency. <i>Blood</i> , 2015, 126, 4548-4548.	1.4	1
76	Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing. <i>Blood</i> , 2015, 126, 73-73.	1.4	6
77	The Phenotypic Spectrum of Pyruvate Kinase Deficiency (PKD) from the PKD Natural History Study (NHS): Description of Four Severity Groups By Anemia Status. <i>Blood</i> , 2015, 126, 2136-2136.	1.4	1
78	The use of erythropoietin-stimulating agents versus supportive care in newborns with hereditary spherocytosis: a single centre's experience. <i>European Journal of Haematology</i> , 2014, 93, 161-164.	2.2	9
79	Standardized Clinical Assessment and Management Plans (SCAMPs): Perspectives on a New Method to Understand Treatment Decisions and Outcomes in Immune Thrombocytopenia. <i>Seminars in Hematology</i> , 2013, 50, S31-S38.	4.0	4
80	A phase 2 study of the safety, tolerability, and pharmacodynamics of FBS0701, a novel oral iron chelator, in transfusional iron overload. <i>Blood</i> , 2012, 119, 3263-3268.	1.4	48
81	Applicability of 2009 international consensus terminology and criteria for immune thrombocytopenia to a clinical pediatric population. <i>Pediatric Blood and Cancer</i> , 2012, 58, 216-220.	1.6	18
82	Response to steroids predicts response to rituximab in pediatric chronic immune thrombocytopenia. <i>Pediatric Blood and Cancer</i> , 2012, 58, 221-225.	1.6	29
83	Trends in anti-D immune globulin for childhood immune thrombocytopenia: Usage, response rates, and adverse effects. <i>American Journal of Hematology</i> , 2012, 87, 315-317.	4.3	15
84	The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. <i>British Journal of Haematology</i> , 2011, 152, 452-459.	2.7	219
85	Resolution of cerebral artery stenosis in a child with sickle cell anemia treated with hydroxyurea. <i>American Journal of Hematology</i> , 2010, 85, 135-137.	4.3	3
86	Genetic studies in pediatric ITP: outlook, feasibility, and requirements. <i>Annals of Hematology</i> , 2010, 89, 95-103.	1.8	48
87	Unsuspected Pulmonary Emboli in Pediatric Oncology Patients: Detection With MDCT. <i>American Journal of Roentgenology</i> , 2010, 194, 1216-1222.	2.8	21
88	The North American Chronic Immune Thrombocytopenia Registry (NACIR): Demographics and Treatment Responses. <i>Blood</i> , 2010, 116, 2509-2509.	1.4	0
89	Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. <i>Pediatric Blood and Cancer</i> , 2009, 52, 865-867.	1.6	10
90	Compliance with Immunizations in Splenectomized Individuals: A Study of the Splenectomized Hereditary Spherocytosis Population. <i>Blood</i> , 2008, 112, 1316-1316.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Utilization of an ITP quality improvement pathway improves adherence to management guidelines. <i>Pediatric Blood and Cancer</i> , 0, , .	1.6	0
92	Comorbidities and complications in adult and paediatric patients with pyruvate kinase deficiency: Analysis from the Peak Registry. <i>British Journal of Haematology</i> , 0, , .	2.7	0
93	Quality of life in childhood immune thrombocytopenia: Revision of the Kids' <scp>ITP</scp> Tools (<scp>KIT</scp>). <i>British Journal of Haematology</i> , 0, , .	2.7	0
94	What's in a name: defining pediatric refractory ITP. <i>Blood Advances</i> , 0, , .	5.4	0
95	Genetic Variants in Canonical Wnt Signaling Pathway Associated with Pediatric Immune Thrombocytopenia. <i>Blood Advances</i> , 0, , .	5.4	0